)
Danaher (DHR) investor relations material
Danaher Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic priorities and commercial execution
Ambition: higher, sustainable profitable core growth and unambiguous share gain; priorities are commercial excellence, innovation, talent and capital allocation.
Commercial focus includes stronger funnel management and account plans, plus a key-account layer connecting customers with multiple operating companies.
Connected diagnostic selling has created several hundred million dollars of incremental opportunity.
Innovation strategy will direct organic R&D toward the strongest growth opportunities; annual innovation spending is ~$1.7B, viewed as the right level, with added science and technology talent.
In diagnostics, focused innovation priorities increased forecasted growth from innovation by 80%.
Growth playbook and innovation opportunities
Diagnostics revenue grew from $6B in 2017 to $11B, with 3x the operating profit; core growth ex-respiratory in China more than doubled over the last handful of years.
Leica Biosystems improved from mid-single-digit to high-single-digit growth through stronger commercial execution, including funnel management and account planning.
Leica Biosystems is investing in companion diagnostics and pharma services; its quantitative companion diagnostics pipeline is growing, with material P&L impact expected only after development stages.
Priority innovation areas include blood-based Alzheimer’s biomarkers, oncology, AI drug discovery and process intensification; Alzheimer’s testing could become a $5B market in 10 years, with 150+ disease-modifying therapies in the pipeline.
Capital allocation and M&A
M&A remains the capital deployment priority, focused on differentiated growth and strengthening the three platforms; more than $11B was deployed this year, including Masimo and StatLab.
Masimo and StatLab are expected to deliver high-single-digit ROICs by year five or earlier; buybacks remain opportunistic and the dividend is a commitment.
A lesson from Aldevron was to assess technology and product adoption curves thoroughly after cell and gene therapy adoption timing was misjudged.
- Growth strategy centers on share gains, innovation and cross-selling, with reshoring revenue from 2028 onward.DHR
UBS Global Healthcare Conference - Q3 sales and adjusted EPS grew; FY 2026 EPS guidance rose to $8.57–$8.62.DHR
Q3 2026 - Emerging markets drove growth, with localization and local reach central to expansion.DHR
Investor update - Q2 2026 revenue up 5.5%, net earnings $870M, and full-year EPS guidance raised.DHR
Q2 2026 - All board nominees, auditor appointment, and executive pay were approved by large majorities.DHR
AGM 2025 - All proposals passed with strong support amid robust financial performance and strategic focus.DHR
AGM 2026 - Strong growth in bioprocessing and diagnostics supports a positive full-year outlook.DHR
Bank of America Global Healthcare Conference 2026 - Bioprocessing and diagnostics drive growth outlook, with Masimo acquisition boosting long-term returns.DHR
TD Cowen 46th Annual Health Care Conference - Strong Q4 results, robust recurring revenue, and high single-digit growth outlook driven by innovation.DHR
43rd Annual J.P. Morgan Healthcare Conference 2025
)
)
)
)
)
)
)
)